Naggie, 1,359 patient HCQ prophylaxis RCT: 24% fewer symptomatic cases [p=0.18] https://c19p.org/naggie
copied to clipboard
Hydroxychloroquine for pre-exposure prophylaxis of COVID-19 in health care workers: a randomized, multicenter, placebo-controlled trial (HERO-HCQ)
et al., medRxiv, doi:10.1101/2021.08.19.21262275 (Preprint)
RCT 1,360 healthcare workers in the USA showing OR 0.75 [0.49-1.15] for confirmed or suspected COVID-19 clinical infection by day 30. There were no significant safety issues. Authors note that pooling the results with the COVID PREP study gives OR 0.74 [0.55-1.0] p = 0.046. NCT04334148.
|
risk of symptomatic case, 23.5% lower, RR 0.76, p = 0.18, treatment 41 of 683 (6.0%), control 53 of 676 (7.8%), NNT 54, odds ratio converted to relative risk, logistic regression.
|
|
risk of symptomatic case, 29.3% lower, RR 0.71, p = 0.18, treatment 41 of 683 (6.0%), control 53 of 676 (7.8%), NNT 54, odds ratio converted to relative risk, Mantel–Haenszel.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Naggie et al., 8/25/2021, Randomized Controlled Trial, USA, North America, preprint, 22 authors, trial NCT04334148.
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.